Although the use of ATP-competitive tyrosine kinase inhibitors of oncoprotein BCR-ABL1
has enabled durable responses in patients with chronic myeloid leukemia (CML), issues of …

Bruton tyrosine kinase (BTK) is an important signaling hub that activates the B-cell receptor
(BCR) signaling cascade. BCR activation can contribute to the growth and survival of B-cell …

Escape from apoptosis is one of the major hallmarks of cancer cells. The B-cell Lymphoma 2
(BCL-2) gene family encodes pro-apoptotic and anti-apoptotic proteins that are key …

The intracellular protein B‐cell‐lymphoma‐2 (BCL2) has been considered an attractive
target for cancer therapy since the discovery of its function as a major promoter of cell …

Proteolysis targeting chimera (PROTAC) is an emerging protein degradation strategy, which
shows excellent advantages in targeting those so-called “undruggable” proteins. However …

The clinical development of drug combinations is typically achieved through trial-and-error
or via insight gained through a detailed molecular understanding of dysregulated signaling …

Targeted therapy: An elusive cancer target | Nature Skip to main content Thank you for visiting
nature.com. You are using a browser version with limited support for CSS. To obtain the best …

Abstract The BH3-mimetic ABT-737 and an orally bioavailable compound of the same class,
navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and early …

Targeted protein degradation (TPD) strategies have revolutionized how scientists tackle
challenging protein targets deemed undruggable with traditional small molecule inhibitors …

Apoptosis is a highly regulated cellular process. Aberration in apoptosis is a common
characteristic of various disorders. Therefore, proteins involved in apoptosis are prime …